The goal of the NCI's Antibody Characterization Program (ACP) is to have three monoclonal antibodies produced for each successfully expressed/purified recombinant antigen and one antibody per peptide (1 to 3 peptides per protein). To date over 3000 clones have been screened before selecting the current 265 antibodies. They are winnowed down based on the projected end use of the antibody. The ACP then selects up to three monoclonal antibodies that are then extensively characterized ( Enzyme Linked ImmunoSorbent Assay (ELISA), Western Blot, Immunohistochemistry (IHC), Immuno-mass spectrometry (MS), Surface Plamon Resonance (SPR) and Nucleic Acid Programmable Protein Array (NAPPA) ) and made available to the scientific community.
The text and trademark CPTC Characterized Antibody denotes the antibodies listed on the Antibody Portal. These antibodies with the term “CPTC” have been initially characterized through a standardized process (see above) and the data from this analysis is publicly available through the National Cancer Institute. "CPTC" stands for Clinical Proteomic Technologies for Cancer Initiative.